表紙
市場調査レポート

世界のポイントオブケア(POC)診断市場

Point of Care Diagnostics

発行 BCC Research 商品コード 228049
出版日 ページ情報 英文 224 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
世界のポイントオブケア(POC)診断市場 Point of Care Diagnostics
出版日: 2014年04月07日 ページ情報: 英文 224 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

2012年に151億米ドルを記録した世界におけるポイントオブケア(POC)診断市場は、2013年には155億米ドルに達する見通しです。また、同市場は今後5年間のCAGRが4.5%で拡大し、2018年には193億米ドルとなる見込みです。

当レポートでは、世界におけるポイントオブケア(POC)診断市場の現状と将来予測、成長への影響因子や課題、主要参入企業のプロファイルなどを提供しており、概略以下の構成でお届けします。

第1章 イントロダクション

第2章 サマリー

第3章 概要

  • POC検査とは?
  • 業界用語
  • 臨床診断産業構造におけるPOC
  • POC製品の区分
  • 一般的なPOC検査
  • 米国におけるCLIAの重要性
  • POC検査におけるFDAの役割
  • POC市場の発展要因
  • 薬物乱用に関する注目

第4章 世界のPOC市場

  • 市場概要
  • 市場構造
    • 流通
    • プロモーション
    • 戦略的アライアンス・買収
  • 市場コンポーネント
    • 血液化学・電解質検査
    • 心臓マーカー検査
    • コレステロール検査
    • 薬物・アルコール中毒検査
    • 血糖値検査
    • 感染症検査
    • 妊娠・受胎能試験
    • ヘモグロビン/止血
    • 腫瘍マーカー検査
    • 尿化学検査
    • MISC検査

第5章 血液化学・電解質検査

  • セグメントの概要
  • 血液化学パラメーター
  • 市場規模

第6章 心臓マーカー検査

  • セグメント概要
  • 市場規模
  • 市場参入企業・市場シェア

第7章 コレステロール検査

第8章 薬物・アルコール中毒検査

第9章 血糖値検査

第10章 感染症検査

第11章 妊娠・受胎能試験

第12章 ヘモグロビン/止血検査

第13章 腫瘍マーカー検査

第14章 尿化学検査

第15章 MISC検査

第16章 技術アプリケーション

第17章 世界のPOC市場

  • 総市場規模
  • 米国市場の規模
  • 国際市場の規模
  • 世界市場のシェア
  • 世界市場におけるメーカーのプレゼンス

第18章 主な市場参入企業のプロファイル

  • 市場参入企業の概要
  • 企業プロファイル

第19章 付録

図表リスト

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: HLC043D

BCC Research estimates the global market for point-of-care (POC) diagnostics to have been almost $15.1 billion in 2012. The market should reach $15.5 billion in 2013 and $19.3 billion in 2018, a compound annual growth rate (CAGR) of 4.5% over the next five years.

This report provides:

  • An overview of the global market for point of care diagnostics.
  • Analyses of global market trends, with data from 2012 and 2013, and estimates and projections of CAGRs through 2018.
  • Discussion of factors driving the market including staff shortages, older populations, long-term cost savings, and need for faster diagnosis and care.
  • A look at how availability of POC testing has revolutionized the continuum of the patient-care process.

REPORT SCOPE

INTRODUCTION

STUDY GOALS AND OBJECTIVES

The goal of this study on the point-of-care (POC) industry is to describe and review business opportunities in the thriving near-patient testing market. This report provides a complete review and analysis of the current POC markets, and forecasts the market through 2018 in constant U.S. dollars. In addition, it provides an examination and description of select products, current and emerging technologies, and company profiles.

The study also covers issues regarding regulation of POC testing, international developments and patents for POC testing technologies.

REASONS FOR DOING THE STUDY

Over the last few decades, there has been a strong trend toward POC testing due to an increasing demand for near-patient testing that provides rapid results. More tests are being performed at the hospital patient's bedside, in physicians' office laboratories, outpatient clinics, emergency rooms and intensive-care units. Critical-care instruments combining selected important chemistry, hematology and hemostasis parameters have entered the market for POC testing in emergency and operating rooms.

The wider availability of POC testing has revolutionized the continuum of the patient-care process by providing laboratory results rapidly and efficiently at these locations. The trend toward greater POC testing is driven by the faster diagnostic benefits it provides.

The heightened awareness of testing and identifying treatment targets via diagnostics tests has strengthened the role of POC tests in the health field. Using both diagnostics and treatments as a combination have been important advancements to optimal health treatment.

Several reasons have emerged for this demand of POC testing, including staff shortages, older populations, long-term cost savings, faster diagnosis and care, and rural locations without conventional laboratory services. This study will address these areas and others.

CONTRIBUTION OF THE STUDY AND FOR WHOM

The intended audience includes all the stakeholders of the near-patient diagnostic testng market: diagnostic test manufacturing companies, medical supply vendors, hospitals, physician offices and groups, development companies and other involved participants. This includes mostly manufacturers, suppliers, technology providers, and research and development (R&D) companies.

With its broad scope and in-depth analyses, this study will prove to be a valuable resource to anyone involved with or interested in the development of diagnostics test to the POC segment of the health industry. This study will provide information on these areas:

  • Structure and current market size of the POC market as outlined with forecasts through 2018.
  • Impact of chronic diseases, growing and aging populations.
  • Current product suppliers and some of their technologies.
  • A look at the diagnostic testing industry and trends affecting the market.
  • Markets by each segment provide a global overview showing market data for the U.S., Europe Asia and the rest of the world.
  • Technology patent trends relating to testing processes.
  • Profiles for more than 20 companies in the industry with significant contributions and market shares.

Since the study provides business and technical information of a timely nature, it will prove valuable to a variety of readers, including industry executives, managers and planners, purchasers, industry analysts and investors. The projections, forecasts and trend analyses found in this report provide readers with the necessary data and information for careful decision-making and what products will best meet the needs of the POC segment.

SCOPE OF REPORT

This study will describe the market for POC diagnostics at the global level. It focuses on the accelerating growth in this important diagnostic market segment and the key industry players. Specifically, the report:

  • Describes the POC industry.
  • Estimates the current and future market size.
  • Provides breakdowns for U.S. markets.
  • Describes product segments and the continuous updating of POC products.
  • Analyzes market influences in the industry and predicts the changes that will shape the future POC market.
  • Discusses trends within the market and provides a future outlook.
  • Reviews business activities of market leaders.
  • Lists patents for POC technologies.

DEFINING POC

For the purpose of this study, POC testing includes those tests that are used outside the traditional laboratory. This can be a range of users, including patients, physicians, outpatient clinics, community health centers and pharmacies. Tests included in this report are those that do not require any specialized training to perform, are performed easily and with results that are produced in a minimal time frame. Some other terms often used to describe POC include:

  • Waived tests.
  • Rapid tests.
  • Near-patient testing.
  • Bedside testing.
  • Outpatient testing.

Table of Contents

CHAPTER 1 INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • CONTRIBUTION OF THE STUDY AND FOR WHOM
  • SCOPE OF REPORT
  • DEFINING POC
  • METHODOLOGY
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH ONLINE SERVICES
  • DISCLAIMER

CHAPTER 2 SUMMARY

  • OVERVIEW
  • MAJOR FINDINGS
  • SUMMARY TABLE GLOBAL FORECAST FOR THE POC MARKET, THROUGH 2018 ($ MILLIONS)
  • SUMMARY FIGURE FORECAST OF THE GLOBAL POC MARKET, 2009-2018 ($ MILLIONS)

CHAPTER 3 INDUSTRY OVERVIEW

  • WHAT IS POC TESTING?
  • INDUSTRY TERMS (1)
  • OVERVIEW OF THE POC MARKET
  • POC AS PART OF CLINICAL DIAGNOSTICS INDUSTRY STRUCTURE
    • MEDICAL BENEFITS DERIVED FROM IMMEDIATE DIAGNOSTIC TESTING
    • POC TESTING SITES
    • TABLE 1 SELECTED KEY STATISTICS FOR POC TESTING SITES
    • HOME USE/SELF-CARE
    • EMERGENCY ROOMS (ER)
    • CRITICAL-CARE UNITS (CCU)
    • BEDSIDE TESTING
    • TABLE 2 ESTIMATED NUMBER OF HOSPITALS/INPATIENT ACUTE CARE CENTERS AND BEDS AVAILABLE BY SELECTED COUNTRY, 2013
    • FIGURE 1 ESTIMATED NUMBER OF INPATIENT CARE FACILITIES AND AVAILABLE BEDS BY SELECTED COUNTRY, 2013
    • OPERATING ROOMS (OR)/PROCEDURE ROOMS (PR)
    • PHYSICIANS OFFICES/CLINICS/TREATMENT CENTERS/OTHER NONCRITICAL-CARE SITES 17
      • Nursing Homes and Hospice
      • TABLE 3 NURSING HOMES RESIDENTS BY SELECTED U.S. STATES, 2011
      • TABLE 4 HOSPICE FACTS, 2011 VS. 2012
  • POC PRODUCT SEGMENTS
    • POC CLINICAL ASSAY CATEGORIES
      • Blood Chemistry and Electrolytes
      • Cardiac Marker
      • Cholesterol Testing/Monitoring
      • Drug and Alcohol Screening
      • Glucose Testing and Monitoring
      • Infectious Disease Testing
      • Pregnancy and Fertility Testing
      • Hemoglobin and Hemostasis
      • Tumor Marker
      • Urinalysis/Urine Chemistry
  • COMMONLY PERFORMED POC TESTS
  • TABLE 5 SELECTED POC TESTS-CLIA WAIVED
  • SIGNIFICANCE OF CLIA IN THE UNITED STATES
  • THE FDA'S ROLE IN POC TESTING
    • GOOD MANUFACTURING PRACTICE (GMP)
    • TABLE 6 PERTINENT PARAMETERS OF GMP REGULATIONS AFFECTING IN VITRO DIAGNOSTICS
  • DRIVING FORCES OF THE POC MARKET
    • COST CONTAINMENT
      • Rising Healthcare Costs
      • TABLE 7 HEALTH EXPENDITURES AS PERCENTAGE OF GDP BY SELECT COUNTRY. 1980-2015 (%)
      • FIGURE 2 HEALTH EXPENDITURES AS PERCENTAGE OF GDP BY SELECT COUNTRY, 1980-2015 (%)
      • TABLE 8 HEALTH EXPENDITURES AS PERCENTAGE OF GDP BY COUNTRY: TOP
      • SPENDERS, 2011
      • FIGURE 3 HEALTH EXPENDITURES AS PERCENT OF GDP BY COUNTRY: TOP
      • SPENDERS, 2011 (%)
      • Trends in Hospital Length of Stay
      • TABLE 9 HOSPITAL USAGE STATISTICS, 2003 COMPARED TO 2011 (DAYS)
      • FIGURE 4 HOSPITAL USAGE STATISTICS, 2003 AND 2011 (DAYS)
    • PUBLIC HEALTHCARE SYSTEMS AROUND THE WORLD
    • TABLE 10 WORLD HEALTH ORGANIZATION RANKING OF HEALTHCARE SYSTEMS, TOP 50, 2000
    • GLOBAL SHORTAGE OF HEALTHCARE WORKERS
    • TECHNOLOGICAL ADVANCEMENT
      • Availability-Ease of Use Devices
      • New Technologies
    • INCIDENCE OF DISEASE
    • TABLE 11 STATISTICS OF SELECTED DISEASES IN THE GLOBAL POPULATION, 2012-2013 ESTIMATES
      • Asthma
      • Cardiovascular Disease
      • Cancer
      • Diabetes
      • Diarrheal Disease
      • HIV
      • Infertility
      • Influenza
      • Malaria
      • Pregnancy
      • TABLE 12 BIRTH RATES AND BIRTHS BY COUNTRY, 2013 ESTIMATES (THOUSAND/%)
      • FIGURE 5 BIRTH RATES AND BIRTHS BY COUNTRY, 2013 ESTIMATES (THOUSAND/%)
      • Tuberculosis
  • ATTENTION TO DRUGS OF ABUSE
    • DEMOGRAPHICS AND AGING POPULATIONS
      • Global Demographics
      • TABLE 13 ESTIMATED GLOBAL POPULATION AND ANNUAL GROWTH BY SELECTED AGE GROUP AND SELECTED YEARS, THROUGH 2030 (MILLIONS)
      • FIGURE 6 ESTIMATED GLOBAL POPULATION BY SELECTED AGE GROUP AND SELECTED YEARS, 2000-2030 ($ MILLIONS)
      • TABLE 14 GLOBAL POPULATION BY SELECTED COUNTRY, THROUGH 2015 (MILLIONS)
      • FIGURE 7 GLOBAL POPULATION BY SELECTED COUNTRY, 2010 AND 2015 (MILLIONS)
        • Global Life Expectancy
        • TABLE 15 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2010 (YEARS)
        • FIGURE 8 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2010 (YEARS)
      • U.S. Demographics
      • TABLE 16 U.S. POPULATION ESTIMATES AND PROJECTIONS BY AGE GROUP, 1900-2050 (THOUSANDS)
      • FIGURE 9 U.S. POPULATION ESTIMATES AND PROJECTIONS BY AGE GROUP, 1900 TO 2050 (THOUSANDS)
        • Gender, Age and Life Expectancy
        • TABLE 17 ESTIMATES OF EXPECTED U.S. LIFE EXPECTANCY AT BIRTH WITH PROJECTIONS BY SEX, 1990-2020 (YEARS)
        • FIGURE 10 ESTIMATES OF EXPECTED U.S. LIFE EXPECTANCY AT BIRTH WITH PROJECTIONS BY SEX, 1990-2020 (YEARS)
        • TABLE 18 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2013 (YEARS)
        • FIGURE 11 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2013 (YEARS)

CHAPTER 4 THE GLOBAL POC MARKET

  • MARKET OVERVIEW
  • TABLE 19 GLOBAL FORECAST FOR THE POC MARKET BY TEST TYPE, THROUGH 2018 ($ MILLIONS)
  • FIGURE 12 GLOBAL FORECAST FOR THE POC MARKET BY TEST TYPE, 2009-2018 ($ MILLIONS)
  • FIGURE 13 DISTRIBUTION OF SALES FOR THE GLOBAL POC MARKET BY TEST TYPE, 2013 (%)
  • COMPETITOR MARKET SHARE
  • TABLE 20 MARKET SHARE OF MAJOR POC MARKET PARTICIPANTS, 2013 ($ MILLIONS)
  • FIGURE 14 MARKET SHARE MAJOR POC MARKET PARTICIPANTS, 2013 (%)
  • MARKET STRUCTURE
    • DISTRIBUTION
    • FIGURE 15 DISTRIBUTION CHANNELS: POC DIAGNOSTIC DEVICES
    • PROMOTION
    • STRATEGIC ALLIANCES AND MERGERS
  • MARKET COMPONENTS
    • BLOOD CHEMISTRY AND ELECTROLYTE TESTING
    • CARDIAC MARKER TESTING
    • CHOLESTEROL TESTING
    • DRUG AND ALCOHOL ABUSE TESTING
    • GLUCOSE TESTING
    • INFECTIOUS DISEASE TESTING
    • PREGNANCY AND FERTILITY TESTING
    • HEMATOLOGY AND HEMOSTASIS TESTING
    • TUMOR MARKER TESTING
    • URINE CHEMISTRY TESTING
    • MISCELLANEOUS POC TESTING

CHAPTER 5 BLOOD CHEMISTRY AND ELECTROLYTE TESTING

  • SEGMENT OVERVIEW
  • BLOOD CHEMISTRY PARAMETERS
    • ELECTROLYTES
      • CLIA Quality Control (QC) Requirements for Blood Gas Analysis
  • MARKET SIZE
  • TABLE 21 FORECAST OF THE GLOBAL POC BLOOD GAS/ELECTROLYTE TESTING MARKET, THROUGH 2018 ($ MILLIONS)
  • FIGURE 16 FORECAST OF THE GLOBAL POC BLOOD GAS/ELECTROLYTE TESTING MARKET, 2009-2018 ($ MILLIONS)
  • MARKET PARTICIPANTS AND MARKET SHARES
  • TABLE 22 RELATIVE MARKET SHARE OF POC BLOOD CHEMISTRY ANALYZER MANUFACTURERS, 2013 (%/$ MILLIONS)
  • FIGURE 17 RELATIVE MARKET SHARE BLOOD GAS ANALYZER MANUFACTURERS, 2013 (%)
    • ABBOTT DIAGNOSTICS
      • i-STAT
    • ABAXIS
      • Piccolo Classic and Piccolo Xpress
      • TABLE 23 ABAXIS PICCOLO ANALYZER TEST AVAILABILITY
    • ALERE
      • Epoc Blood Analysis System
    • INTERNATIONAL TECHNIDYNE CORP. (ITC)
      • IRMA TRUpoint Blood Analysis System
      • AVOXimeter Whole Blood CO-Oximeter/Oximeter System
    • NOVA BIOMEDICAL
      • Stat Profile pHOx Product Line
      • TABLE 24 NOVA BIOCHEMICAL POC STAT PROFILE PHOX SERIES BY AVAILABLE TESTS
    • RADIOMETER AMERICA INC.
      • ABL80, ABL90 FLEX, ABL800 FLEX
    • ROCHE DIAGNOSTICS
      • Cobas b 121 System
      • Cobas b 221 Blood Gas System
    • SIEMENS HEALTHCARE
      • Rapidpoint 400/405
      • RAPIDComm Data Management System

CHAPTER 6 CARDIAC MARKER TESTING

  • SEGMENT OVERVIEW
  • MARKET SIZE
  • TABLE 25 FORECAST OF THE GLOBAL POC CARDIAC MARKER TESTING MARKET, THROUGH 2018 ($ MILLIONS)
  • FIGURE 18 FORECAST OF THE GLOBAL POC CARDIAC MARKER TESTING MARKET, 2009-2018 ($ MILLIONS)
  • MARKET PARTICIPANTS AND MARKET SHARES
  • TABLE 26 RELATIVE MARKET SHARE OF POC CARDIAC MARKER MANUFACTURERS, 2013 (%/$ MILLIONS)
  • FIGURE 19 RELATIVE MARKET SHARE OF POC CARDIAC MARKER MANUFACTURERS, 2013 (%)
  • TABLE 27 RECENT (2010-2013) CLIA-WAIVED APPROVED CARDIAC MARKER TESTS
    • ABBOTT
      • iSTAT 1
    • ALERE
      • Triage System
      • Triage BNP Test.
      • Heart Check System
    • ROCHE
      • Cobas h 232 System
    • RESPONSE BIOMEDICAL
      • RAMP System
    • SIEMENS
      • Stratus CS Acute Care Diagnostic System

CHAPTER 7 CHOLESTEROL TESTING

  • SEGMENT OVERVIEW
  • MARKET SIZE
  • TABLE 28 FORECAST OF THE GLOBAL CHOLESTEROL POC RAPID TEST MARKET, THROUGH 2018 ($ MILLIONS)
  • FIGURE 20 FORECAST OF THE GLOBAL CHOLESTEROL POC RAPID TEST MARKET, 2009-2018 ($ MILLIONS)
  • MARKET PARTICIPANTS AND MARKET SHARES
  • TABLE 29 RELATIVE MARKET SHARE OF CHOLESTEROL POC RAPID TEST MANUFACTURERS, 2013 (%/$ MILLIONS)
  • FIGURE 21 RELATIVE MARKET SHARE OF CHOLESTEROL POC RAPID TEST MANUFACTURERS, 2013 (%)
  • TABLE 30 RECENT (2010-2013) CLIA-WAIVED APPROVED CHOLESTEROL TESTS
    • ABAXIS
    • ALERE
    • ROCHE DIAGNOSTICS

CHAPTER 8 DRUG AND ALCOHOL ABUSE TESTING

  • SEGMENT OVERVIEW
  • MARKET SIZE
  • TABLE 31 FORECAST OF THE GLOBAL DRUG AND ALCOHOL POC RAPID TEST MARKET, THROUGH 2018 ($ MILLIONS)
  • FIGURE 22 FORECAST OF THE GLOBAL DRUG AND ALCOHOL POC RAPID TEST MARKET, 2009-2018 ($ MILLIONS)
  • MARKET PARTICIPANTS AND MARKET SHARES
  • TABLE 32 RELATIVE MARKET SHARE OF DRUG AND ALCOHOL POC RAPID TEST MANUFACTURERS, 2013 (%/$ MILLIONS)
  • FIGURE 23 RELATIVE MARKET SHARE OF DRUG AND ALCOHOL POC RAPID TEST MANUFACTURERS, 2013 (%)
  • TABLE 33 RECENT (2010-2013) CLIA-WAIVED APPROVED POC DRUG AND ALCOHOL SCREENING TESTS
    • ALERE
    • ORASURE TECHNOLOGIES
    • PHAMATECH

CHAPTER 9 GLUCOSE TESTING

  • SEGMENT OVERVIEW
  • MARKET SIZE
  • TABLE 34 FORECAST OF THE GLOBAL POC GLUCOSE METER MARKET, THROUGH 2018 ($ MILLIONS)
  • FIGURE 24 FORECAST OF THE GLOBAL POC GLUCOSE METER MARKET, 2009-2018 ($ MILLIONS)
  • MARKET PARTICIPANTS AND MARKET SHARES
  • TABLE 35 RELATIVE MARKET SHARE FOR GLUCOSE METERS AND SUPPLIES MANUFACTURERS, 2013 (%/$ MILLIONS)
  • FIGURE 25 RELATIVE MARKET SHARE FOR GLUCOSE METERS AND SUPPLIES MANUFACTURERS, 2013 (%)
  • TABLE 36 RECENT (2010-2013) CLIA-WAIVED APPROVED BLOOD GLUCOSE METERS
    • ROCHE DIAGNOSTICS
      • Accu-Chek Nano Meter System
      • Accu-Chek Aviva Meter System
      • Accu-Chek Compact Plus Meter System
      • Accu-Chek Active System
      • Accu-Chek Inform System
      • Accu-Chek Inform II
      • Accu-Chek Voicemate System
    • JOHNSON AND JOHNSON
      • LifeScan - OneTouch Ultra 2 Meter
      • LifeScan - OneTouch UltraMini
      • LifeScan - OneTouch Verio and Verio IQ
      • LifeScan OneTouch InDuo System
      • LifeScan OneTouch Basic Meter
      • LifeScan OneTouch SureStep Meter
      • LifeScan OneTouch UltraLink Meter
      • LifeScan OneTouch Diabetes Management Software
    • ABBOTT DIABETES CARE
      • FreeStyle Blood Glucose Monitoring System
      • Precision Blood Glucose and Ketone Monitoring Systems
      • i-STAT 1
    • NIPRO DIAGNOSTICS
      • Sidekick Testing System
      • TrueTrack Smart System
    • SIEMENS
      • DCA Vantage Analyzer
      • Home Diagnostic Meters-Retailers
      • TABLE 37 SELECTED LISTING OF RETAILERS SELLING HOME DIAGNOSTIC'S METERS
      • Data Management Systems
      • TABLE 38 SELECT LISTING OF BLOOD GLUCOSE MONITORS CAPABLE OF INTERACTING WITH COMPUTER SOFTWARE

CHAPTER 10 INFECTIOUS DISEASE TESTING

  • SEGMENT OVERVIEW
  • MARKET SIZE
  • TABLE 39 FORECAST OF THE GLOBAL INFECTIOUS DISEASE POC RAPID TEST MARKET, THROUGH 2018 ($ MILLIONS)
  • FIGURE 26 FORECAST OF THE GLOBAL INFECTIOUS DISEASE POC RAPID TEST MARKET, 2009-2018 ($ MILLIONS)
  • TABLE 40 ESTIMATED MARKET SHARE FOR THE GLOBAL POC INFECTIOUS DISEASE MARKET BY TEST TYPE, 2013 (%/$ MILLIONS)
  • FIGURE 27 ESTIMATED MARKET SHARE FOR THE GLOBAL POC INFECTIOUS DISEASE MARKET BY TEST TYPE, 2013 (%)
  • MARKET PARTICIPANTS AND MARKET SHARES
  • TABLE 41 RELATIVE MARKET SHARE OF INFECTIOUS DISEASE POC RAPID TEST MANUFACTURERS, 2013 (%/$ MILLIONS)
  • FIGURE 28 RELATIVE MARKET SHARE OF INFECTIOUS DISEASE POC RAPID TEST MANUFACTURERS, 2013 (%)
    • STREP A
    • INFLUENZA
    • CHLAMYDIA
    • SPECIFIC PRODUCTS FOR TESTING
      • Strep A
      • TABLE 42 RECENT (2010-2013) CLIA-WAIVED APPROVED STREP A TESTS
        • Alere Inc.
        • Beckman Coulter
        • BTNX Inc.
        • Quidel
      • Influenza
      • TABLE 43 RECENT (2010-2013) CLIA-WAIVED APPROVED INFLUENZA TESTS
        • Alere Inc.
        • Becton Dickinson
        • OraSure Technologies
        • Quidel
        • SA Scientific
      • Chlamydia/Trichomoniasis
      • TABLE 44 RECENT (2010-2013) CLIA-WAIVED APPROVED CHLAMYDIA/TRICHOMONAS TESTS
        • Quidel
        • Sekisui Diagnostics
      • RSV
      • TABLE 45 RECENT (2010-2013) CLIA-WAIVED APPROVED RSV TESTS
        • Alere
        • BTNX Inc.
        • Quidel
      • HIV Testing
      • TABLE 46 RECENT (2010-2013) CLIA-WAIVED APPROVED HIV TESTS
        • Alere Inc.
        • OraSure Technologies
        • Trinity Biotech plc
        • Infectious Mononucleosis
        • TABLE 47 RECENT (2010-2013) CLIA-WAIVED APPROVED INFECTIOUS MONONUCLEOSIS TESTS
        • Beckman Coulter
        • Quidel
      • H. pylori
      • TABLE 48 RECENT (2010-2013) CLIA-WAIVED APPROVED H. PYLORI TESTS
        • Quidel
      • Herpes Simplex Virus (HSV)
        • Trinity Biotech
      • Syphilis Treponemal
        • Trinity Biotech
      • Hepatitis C Virus (HCV)
      • TABLE 49 RECENT (2010-2013) CLIA-WAIVED APPROVED HCV TESTS
      • S. Pneumoniae
        • Trinity Biotech
      • Adenovirus
      • TABLE 50 RECENT (2010-2013) CLIA-WAIVED APPROVED ADENOVIRUS TESTS

CHAPTER 11 PREGNANCY AND FERTILITY TESTING

  • SEGMENT OVERVIEW
  • MARKET SIZE
  • TABLE 51 FORECAST OF THE GLOBAL PREGNANCY/FERTILITY POC RAPID TEST MARKET, THROUGH 2018
  • FIGURE 29 FORECAST OF THE GLOBAL INFECTIOUS DISEASE POC RAPID TEST MARKET, 2009-2018 ($ MILLIONS)
  • TABLE 52 MARKET SHARE FOR THE GLOBAL POC PREGNANCY/FERTILITY MARKET BY TEST TYPE, 2013 (%/$ MILLIONS)
  • FIGURE 30 MARKET SHARE FOR THE GLOBAL POC PREGNANCY/FERTILITY MARKET BY TEST TYPE, 2013 (%)
  • MARKET PARTICIPANTS AND MARKET SHARES
  • TABLE 53 RELATIVE MARKET SHARE OF PREGNANCY/FERTILITY POC RAPID TEST MANUFACTURERS, 2013 (%/$ MILLIONS)
  • FIGURE 31 RELATIVE MARKET SHARE OF PREGNANCY/FERTILITY POC RAPID TEST MANUFACTURERS, 2013
  • TABLE 54 RECENT (2010-2013) CLIA-WAIVED APPROVED PREGNANCY TESTS

CHAPTER 12 HEMOGLOBIN/HEMOSTASIS TESTING

  • HEMATOLOGY AND HEMOSTASIS
  • HEMOSTASIS (COAGULATION)
  • MARKET SIZE
  • TABLE 55 FORECAST OF THE GLOBAL HEMOGLOBIN/HEMOSTASIS POC RAPID TEST MARKET, THROUGH 2018 ($ MILLIONS)
  • FIGURE 32 FORECAST OF THE GLOBAL HEMOGLOBIN/HEMOSTASIS POC RAPID TEST MARKET, 2009-2018 ($ MILLIONS)
  • MARKET PARTICIPANTS AND MARKET SHARES
  • TABLE 56 RELATIVE MARKET SHARE OF HEMOGLOBIN/HEMOSTASIS POC RAPID TEST MANUFACTURERS, 2013 (%/$ MILLIONS)
  • FIGURE 33 RELATIVE MARKET SHARE OF HEMOGLOBIN/HEMOSTASIS POC RAPID TEST MANUFACTURERS, 2013 (%)
  • TABLE 57 RECENT (2010-2013) CLIA-WAIVED APPROVED HEMATOLOGY TESTS
    • ALERE
    • ROCHE

CHAPTER 13 TUMOR MARKER TESTING

  • SEGMENT OVERVIEW
  • FECAL AND GASTRIC OCCULT BLOOD
  • BLADDER TUMOR ANTIGEN TEST
  • MARKET SIZE
  • TABLE 58 FORECAST OF THE GLOBAL TUMOR MARKER POC RAPID TEST MARKET, THROUGH 2018 ($ MILLIONS)
  • FIGURE 34 FORECAST OF THE GLOBAL TUMOR MARKER POC RAPID TEST MARKET, 2009-2018 ($ MILLIONS)
  • MARKET PARTICIPANTS AND MARKET SHARES
  • TABLE 59 RELATIVE MARKET SHARE OF TUMOR MARKER POC RAPID TEST MANUFACTURERS, 2013 (%/$ MILLIONS)
  • FIGURE 35 RELATIVE MARKET SHARE OF TUMOR MARKER POC RAPID TEST MANUFACTURERS, 2013 (%)
  • TABLE 60 RECENT (2010-2013) CLIA-WAIVED APPROVED FECAL OCCULT BLOOD TESTS
    • BECKMAN COULTER
    • QUIDEL
    • TABLE 61 RECENT (2010-2013) CLIA-WAIVED APPROVED BLADDER TESTS
    • ALERE

CHAPTER 14 URINE CHEMISTRY TESTING

  • SEGMENT OVERVIEW
  • MARKET SIZE
  • TABLE 62 FORECAST OF THE GLOBAL POC URINE CHEMISTRY ANALYZER MARKET, THROUGH 2018 ($ MILLIONS)
  • FIGURE 36 FORECAST OF THE GLOBAL POC URINE CHEMISTRY ANALYZER MARKET, 2009-2018 ($ MILLIONS)
  • MARKET PARTICIPANTS AND MARKET SHARES
  • TABLE 63 RELATIVE MARKET SHARE OF POC URINE CHEMISTRY ANALYZER MANUFACTURERS, 2013 (%/$ MILLIONS)
  • FIGURE 37 RELATIVE MARKET SHARE OF POC URINE CHEMISTRY ANALYZER MANUFACTURERS, 2013 (%)
  • TABLE 64 RECENT (2010-2013) CLIA-WAIVED APPROVED URINE CHEMISTRY TESTS AND ANALYZERS
  • SIEMENS

CHAPTER 15 MISC. TESTING

  • SEGMENT OVERVIEW
    • VAGINAL PH TESTS
    • TABLE 65 RECENT (2010-2013) CLIA-WAIVED APPROVED VAGINAL PH TESTS
    • THYROID STIMULATING HORMONE (TSH) TESTS
    • TABLE 66 RECENT (2010-2013) CLIA-WAIVED APPROVED TSH TESTS
    • MALE REPRODUCTIVE TESTS
    • TABLE 67 RECENT (2010-2013) CLIA-WAIVED APPROVED MALE REPRODUCTIVE TESTS
    • MENOPAUSE
    • TABLE 68 RECENT (2010-2013) CLIA-WAIVED APPROVED MENOPAUSE TESTS
    • DRY EYE
    • TABLE 69 RECENT (2010-2013) CLIA-WAIVED APPROVED DRY EYE TESTS

CHAPTER 16 TECHNOLOGY APPLICATIONS

  • INTRODUCTION
  • ELECTRONIC DATA MANAGEMENT INTEGRATION
    • POC DEVICE CASE STUDIES-SIEMENS HEALTHCARE
    • ABBOTT I-STAT AND HEALTH RECORDS
  • BIOSENSORS
    • WHAT ARE BIOSENSORS?
      • Catalytic Sensors
      • Affinity Sensors
  • ELECTRODES
    • WHAT ARE ELECTRODES?
  • CONTINUOUS TESTING
    • OCCLUSION SPECTROSCOPY
    • TRANSDERMAL ALCOHOL CONTINUOUS TESTING (TACT)
    • NONINVASIVE ELECTRONIC SKIN SENSORS
  • RAPID HIV TESTS
    • CHEMBIO DIAGNOSTIC SYSTEMS INC.
  • RAPID CLINICAL DRUG TESTING
    • PSYCHEMEDICS CORP.
  • TEARLAB CORP'S OSMOLARITY SYSTEM
  • PATENT ANALYSIS
    • NUMBER OF RECENTLY ISSUED PATENTS
    • TABLE 70 U.S. PATENTS BY POC CATEGORY, JANUARY 2009 TO JANUARY 2014 (NUMBER)
    • FIGURE 38 U.S. PATENTS BY POC CATEGORY, JANUARY 2009 TO JANUARY 2014 (NUMBER)
    • ANALYSIS OF PATENT BY SUBJECT
    • TABLE 71 U.S. PATENTS BY SUBJECT AREA, JANUARY 2009 TO JANUARY 2014 (NUMBER)
    • FIGURE 39 U.S. PATENTS BY SUBJECT AREA, JANUARY 2009 TO JANUARY 2014 (NUMBER)
    • PATENT ASSIGNEES
    • TABLE 72 PATENT ASSIGNEES BY COUNTRY, JANUARY 2013 TO JANUARY 2014
    • FIGURE 40 PATENT ASSIGNEES BY COUNTRY, JANUARY 2013 TO JANUARY 2014 (NO.)
      • Abbott Laboratories
      • AccuVein Inc.
      • Panasonic Corp.
      • Roche Diagnostics Operations Inc.

CHAPTER 17 GLOBAL POC MARKET

  • TOTAL MARKET SIZE
  • TABLE 73 GLOBAL FORECAST FOR THE POC MARKET, THROUGH 2018 ($ MILLIONS)
  • FIGURE 41 GLOBAL FORECAST FOR THE POC MARKET, 2009-2018 ($ MILLIONS)
  • U.S. MARKET SIZE
  • TABLE 74 U.S. FORECAST FOR THE POC MARKET, THROUGH 2018 ($ MILLIONS)
  • FIGURE 42 U.S. FORECAST FOR THE POC MARKET, 2009-2018 ($ MILLIONS)
  • INTERNATIONAL MARKET SIZE
  • TABLE 75 INTERNATIONAL FORECAST FOR THE POC MARKET, THROUGH 2018 ($ MILLIONS)
  • FIGURE 43 INTERNATIONAL FORECAST FOR THE POC MARKET, 2009-2018 ($ MILLIONS)
  • GLOBAL MARKET SHARES
  • TABLE 76 POC GLOBAL MARKET SHARE BY REGION, 2013 (%/$ MILLIONS)
  • FIGURE 44 POC GLOBAL MARKET SHARE BY REGION, 2013 (%)
  • FIGURE 45 NORTH AMERICAN POC MARKET SHARE BY COUNTRY, 2013 (%)
  • FIGURE 46 EUROPEAN POC MARKET SHARE BY COUNTRY, 2013 (%)
  • FIGURE 47 ASIAN POC MARKET SHARE BY COUNTRY, 2013 (%)
  • PRESENCE OF MANUFACTURERS IN THE WORLDWIDE MARKET
  • TABLE 77 MARKET SHARE OF MAJOR POC MARKET PARTICIPANTS, 2013 (%/$ MILLIONS)
  • FIGURE 48 MARKET SHARE MAJOR POC MARKET PARTICIPANTS, 2013 (%)

CHAPTER 18 PROFILES OF MAJOR MARKET PARTICIPANTS

  • OVERVIEW OF MARKET PARTICIPANTS
  • COMPANY PROFILES
    • ABAXIS INC.
    • TABLE 78 ABAXIS' COMPANY REVENUES, 2006-2013* ($ MILLIONS)
    • FIGURE 49 ABAXIS' COMPANY REVENUES, 2006-2013* ($ MILLIONS)
    • ABBOTT LABORATORIES
    • TABLE 79 ABBOTT'S COMPANY REVENUES, 2006-2013 ($ MILLIONS)
    • FIGURE 50 ABBOTTS' COMPANY REVENUES, 2006-2013 ($ MILLIONS)
    • ALERE INC.
    • TABLE 80 ALERE'S COMPANY REVENUES, 2006-2013 ($ MILLIONS)
    • FIGURE 51 ALERE'S COMPANY REVENUES 2006-2013 ($ MILLIONS)
    • BECKMAN COULTER INC.
    • BECTON, DICKINSON AND CO.
    • TABLE 81 BECTON DICKINSON'S COMPANY REVENUES, 2006-2013* ($ MILLIONS)
    • FIGURE 52 BECTON DICKINSON'S COMPANY REVENUES, 2006-2013* ($ MILLIONS)
    • CHEMBIO DIAGNOSTICS INC.
    • TABLE 82 CHEMBIO'S COMPANY SALES, 2006-2013 ($ MILLIONS)
    • FIGURE 53 CHEMBIO'S COMPANY SALES, 2006-2013 ($ MILLIONS)
    • CHURCH & DWIGHT CO. INC.
    • TABLE 83 CHURCH & DWIGHT'S COMPANY REVENUES, 2006-2013 ($ MILLIONS)
    • FIGURE 54 CHURCH & DWIGHT'S COMPANY REVENUES, 2006-2013 ($ MILLIONS)
    • DANAHER CORP.
    • TABLE 84 DANAHER'S COMPANY REVENUES, 2006-2013 ($ MILLIONS)
    • FIGURE 55 DANAHER'S COMPANY REVENUES, 2006-2013 ($ MILLIONS)
    • HEMOCUE AB
    • TABLE 85 HEMOCUE ESTIMATED REVENUES, 2010-2013 ($ MILLIONS)
    • FIGURE 56 HEMOCUE ESTIMATED REVENUES, 2010-2013 ($ MILLIONS)
    • INTERNATIONAL TECHNIDYNE CORP.
    • JOHNSON & JOHNSON
    • TABLE 86 JOHNSON & JOHNSON'S COMPANY REVENUES, 2006-2013 ($ MILLIONS)
    • FIGURE 57 JOHNSON & JOHNSON'S COMPANY REVENUES, 2006-2013 ($ MILLIONS)
    • NIPRO DIAGNOSTICS INC.
    • TABLE 87 NIPRO CORP.'S COMPANY REVENUES, 2006-2013* ($ MILLIONS)
    • FIGURE 58 NIPRO CORP.'S COMPANY REVENUES, 2006-2013* ($ MILLIONS)
    • NOVA BIOMEDICAL
    • ORASURE TECHNOLOGIES
    • TABLE 88 ORASURE'S COMPANY REVENUES, 2006-2013 ($ MILLIONS)
    • FIGURE 59 ORASURE'S COMPANY REVENUES, 2006-2013 ($ MILLIONS)
    • PHAMATECH INC.
    • QUIDEL CORP.
    • TABLE 89 QUIDEL'S COMPANY REVENUES, 2006-2013 ($ MILLIONS)
    • FIGURE 60 QUIDEL'S COMPANY REVENUES, 2006-2013 ($ MILLIONS)
    • RADIOMETER MEDICAL APS
    • ROCHE
    • TABLE 90 ROCHE GROUP'S REVENUES, 2006-2013 ($ MILLIONS)
    • FIGURE 61 ROCHE GROUP'S REVENUES, 2006-2013 ($ MILLIONS)
    • SA SCIENTIFIC, LTD.
    • SEKISUI DIAGNOSTICS
    • TABLE 91 SEKISUI CHEMICAL CO.'S REVENUES, 2006-2013* ($ MILLIONS)
    • FIGURE 62 SEKISUI CHEMICAL CO.'S REVENUES, 2006-2013* ($ MILLIONS)
    • SIEMENS MEDICAL SOLUTIONS
    • TABLE 92 SIEMENS' COMPANY REVENUES, 2006-2013* ($ MILLIONS)
    • FIGURE 63 SIEMENS' COMPANY REVENUES, 2006-2013* ($ MILLIONS)
    • TRINITY BIOTECH PLC
    • TABLE 93 TRINITY'S COMPANY REVENUES, 2006-2013 ($ MILLIONS)
    • FIGURE 64 TRINITY'S COMPANY REVENUES, 2006-2013 ($ MILLIONS)

CHAPTER 19 APPENDIX

  • KEY SOURCES OF INFORMATION
    • ABAXIS, INC
    • ABBOTT LABORATORIES
    • ACON LABORATORIES INC.
    • ALERE INC.
    • ALFA SCIENTIFIC DESIGNS INC.
    • ARKRAY INC.
    • BECKMAN COULTER INC.
    • BECTON, DICKINSON AND CO.
    • BIOMERICA INC.
    • BTNX INC.
    • CHURCH & DWIGHT CO. INC.
    • CLIAWAIVED.COM
    • COAGUSENSE INC.
    • DANAHER CORP.
    • EKF DIAGNOSTICS COMPANY
    • FORA CARE INC.
    • HEMOCUE AB
    • INSIGHT PHARMACEUTICALS, LLC.
    • INTERNATIONAL TECHNIDYNE CORP.
    • JANT PHARMACAL CORP.
    • JOHNSON & JOHNSON
    • MERIDIAN BIOSCIENCE INC.
    • NIPRO DIAGNOSTICS INC.
    • NOVA BIOMEDICAL
    • ORASURE TECHNOLOGIES
    • PHAMATECH INC.
    • PRINCETON BIOMEDITECH CORP.
    • QUEST DIAGNOSTICS
    • QUIDEL CORP.
    • RADIOMETER MEDICAL APS
    • RESPONSE BIOMEDICAL CORP.
    • ROCHE
    • SA SCIENTIFIC, LTD.
    • SEKISUI DIAGNOSTICS
    • SIEMENS MEDICAL SOLUTIONS
    • SPECTRAL DIAGNOSTICS
    • STANBIO LABORATORY
    • SWISS PRECISION DIAGNOSTICS GMBH
    • TRINITY BIOTECH PLC

LIST OF TABLES

  • SUMMARY TABLE GLOBAL FORECAST FOR THE POC MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 1 SELECTED KEY STATISTICS FOR POC TESTING SITES
  • TABLE 2 ESTIMATED NUMBER OF HOSPITALS/INPATIENT ACUTE CARE CENTERS AND BEDS AVAILABLE BY SELECTED COUNTRY, 2013
  • TABLE 3 NURSING HOMES RESIDENTS BY SELECTED U.S. STATES, 2011
  • TABLE 4 HOSPICE FACTS, 2011 VS. 2012
  • TABLE 5 SELECTED POC TESTS-CLIA WAIVED
  • TABLE 6 PERTINENT PARAMETERS OF GMP REGULATIONS AFFECTING IN VITRO DIAGNOSTICS
  • TABLE 7 HEALTH EXPENDITURES AS PERCENTAGE OF GDP BY SELECT COUNTRY. 1980-2015 (%)
  • TABLE 8 HEALTH EXPENDITURES AS PERCENTAGE OF GDP BY COUNTRY: TOP 20 SPENDERS, 2011
  • TABLE 9 HOSPITAL USAGE STATISTICS, 2003 COMPARED TO 2011 (DAYS)
  • TABLE 10 WORLD HEALTH ORGANIZATION RANKING OF HEALTHCARE SYSTEMS, TOP 50, 2000
  • TABLE 11 STATISTICS OF SELECTED DISEASES IN THE GLOBAL POPULATION, 2012-2013 ESTIMATES
  • TABLE 12 BIRTH RATES AND BIRTHS BY COUNTRY, 2013 ESTIMATES (THOUSAND/%)
  • TABLE 13 ESTIMATED GLOBAL POPULATION AND ANNUAL GROWTH BY SELECTED AGE GROUP AND SELECTED YEARS, THROUGH 2030 (MILLIONS)
  • TABLE 14 GLOBAL POPULATION BY SELECTED COUNTRY, THROUGH 2015 (MILLIONS)
  • TABLE 15 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2010 (YEARS)
  • TABLE 16 U.S. POPULATION ESTIMATES AND PROJECTIONS BY AGE GROUP, 1900-2050 (THOUSANDS)
  • TABLE 17 ESTIMATES OF EXPECTED U.S. LIFE EXPECTANCY AT BIRTH WITH PROJECTIONS BY SEX, 1990-2020 (YEARS)
  • TABLE 18 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2013 (YEARS)
  • TABLE 19 GLOBAL FORECAST FOR THE POC MARKET BY TEST TYPE, THROUGH 2018 ($ MILLIONS)
  • TABLE 20 MARKET SHARE OF MAJOR POC MARKET PARTICIPANTS, 2013 ($ MILLIONS)
  • TABLE 21 FORECAST OF THE GLOBAL POC BLOOD GAS/ELECTROLYTE TESTING MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 22 RELATIVE MARKET SHARE OF POC BLOOD CHEMISTRY ANALYZER MANUFACTURERS, 2013 (%/$ MILLIONS)
  • TABLE 23 ABAXIS PICCOLO ANALYZER TEST AVAILABILITY
  • TABLE 24 NOVA BIOCHEMICAL POC STAT PROFILE PHOX SERIES BY AVAILABLE TESTS
  • TABLE 25 FORECAST OF THE GLOBAL POC CARDIAC MARKER TESTING MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 26 RELATIVE MARKET SHARE OF POC CARDIAC MARKER MANUFACTURERS, 2013 (%/$ MILLIONS)
  • TABLE 27 RECENT (2010-2013) CLIA-WAIVED APPROVED CARDIAC MARKER TESTS
  • TABLE 28 FORECAST OF THE GLOBAL CHOLESTEROL POC RAPID TEST MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 29 RELATIVE MARKET SHARE OF CHOLESTEROL POC RAPID TEST MANUFACTURERS, 2013 (%/$ MILLIONS)
  • TABLE 30 RECENT (2010-2013) CLIA-WAIVED APPROVED CHOLESTEROL TESTS
  • TABLE 31 FORECAST OF THE GLOBAL DRUG AND ALCOHOL POC RAPID TEST MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 32 RELATIVE MARKET SHARE OF DRUG AND ALCOHOL POC RAPID TEST MANUFACTURERS, 2013 (%/$ MILLIONS)
  • TABLE 33 RECENT (2010-2013) CLIA-WAIVED APPROVED POC DRUG AND ALCOHOL SCREENING TESTS
  • TABLE 34 FORECAST OF THE GLOBAL POC GLUCOSE METER MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 35 RELATIVE MARKET SHARE FOR GLUCOSE METERS AND SUPPLIES MANUFACTURERS, 2013 (%/$ MILLIONS)
  • TABLE 36 RECENT (2010-2013) CLIA-WAIVED APPROVED BLOOD GLUCOSE METERS
  • TABLE 37 SELECTED LISTING OF RETAILERS SELLING HOME DIAGNOSTIC'S METERS
  • TABLE 38 SELECT LISTING OF BLOOD GLUCOSE MONITORS CAPABLE OF INTERACTING WITH COMPUTER SOFTWARE
  • TABLE 39 FORECAST OF THE GLOBAL INFECTIOUS DISEASE POC RAPID TEST MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 40 ESTIMATED MARKET SHARE FOR THE GLOBAL POC INFECTIOUS DISEASE MARKET BY TEST TYPE, 2013 (%/$ MILLIONS)
  • TABLE 41 RELATIVE MARKET SHARE OF INFECTIOUS DISEASE POC RAPID TEST MANUFACTURERS, 2013 (%/$ MILLIONS)
  • TABLE 42 RECENT (2010-2013) CLIA-WAIVED APPROVED STREP A TESTS
  • TABLE 43 RECENT (2010-2013) CLIA-WAIVED APPROVED INFLUENZA TESTS
  • TABLE 44 RECENT (2010-2013) CLIA-WAIVED APPROVED CHLAMYDIA/TRICHOMONAS TESTS
  • TABLE 45 RECENT (2010-2013) CLIA-WAIVED APPROVED RSV TESTS
  • TABLE 46 RECENT (2010-2013) CLIA-WAIVED APPROVED HIV TESTS
  • TABLE 47 RECENT (2010-2013) CLIA-WAIVED APPROVED INFECTIOUS MONONUCLEOSIS TESTS
  • TABLE 48 RECENT (2010-2013) CLIA-WAIVED APPROVED H. PYLORI TESTS
  • TABLE 49 RECENT (2010-2013) CLIA-WAIVED APPROVED HCV TESTS
  • TABLE 50 RECENT (2010-2013) CLIA-WAIVED APPROVED ADENOVIRUS TESTS
  • TABLE 51 FORECAST OF THE GLOBAL PREGNANCY/FERTILITY POC RAPID TEST MARKET, THROUGH 2018
  • TABLE 52 MARKET SHARE FOR THE GLOBAL POC PREGNANCY/FERTILITY MARKET BY TEST TYPE, 2013 (%/$ MILLIONS)
  • TABLE 53 RELATIVE MARKET SHARE OF PREGNANCY/FERTILITY POC RAPID TEST MANUFACTURERS, 2013 (%/$ MILLIONS)
  • TABLE 54 RECENT (2010-2013) CLIA-WAIVED APPROVED PREGNANCY TESTS
  • TABLE 55 FORECAST OF THE GLOBAL HEMOGLOBIN/HEMOSTASIS POC RAPID TESTfMARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 56 RELATIVE MARKET SHARE OF HEMOGLOBIN/HEMOSTASIS POC RAPID TESTfMANUFACTURERS, 2013 (%/$ MILLIONS)
  • TABLE 57 RECENT (2010-2013) CLIA-WAIVED APPROVED HEMATOLOGY TESTS
  • TABLE 58 FORECAST OF THE GLOBAL TUMOR MARKER POC RAPID TEST MARKET,fTHROUGH 2018 ($ MILLIONS)
  • TABLE 59 RELATIVE MARKET SHARE OF TUMOR MARKER POC RAPID TESTfMANUFACTURERS, 2013 (%/$ MILLIONS)
  • TABLE 60 RECENT (2010-2013) CLIA-WAIVED APPROVED FECAL OCCULT BLOODfTESTS
  • TABLE 61 RECENT (2010-2013) CLIA-WAIVED APPROVED BLADDER TESTS
  • TABLE 62 FORECAST OF THE GLOBAL POC URINE CHEMISTRY ANALYZER MARKET,fTHROUGH 2018 ($ MILLIONS)
  • TABLE 63 RELATIVE MARKET SHARE OF POC URINE CHEMISTRY ANALYZER MANUFACTURERS, 2013 (%/$ MILLIONS)
  • TABLE 64 RECENT (2010-2013) CLIA-WAIVED APPROVED URINE CHEMISTRY TESTS AND ANALYZERS
  • TABLE 65 RECENT (2010-2013) CLIA-WAIVED APPROVED VAGINAL PH TESTS
  • TABLE 66 RECENT (2010-2013) CLIA-WAIVED APPROVED TSH TESTS
  • TABLE 67 RECENT (2010-2013) CLIA-WAIVED APPROVED MALE REPRODUCTIVE TESTS
  • TABLE 68 RECENT (2010-2013) CLIA-WAIVED APPROVED MENOPAUSE TESTS
  • TABLE 69 RECENT (2010-2013) CLIA-WAIVED APPROVED DRY EYE TESTS
  • TABLE 70 U.S. PATENTS BY POC CATEGORY, JANUARY 2009 TO JANUARY 2014 (NUMBER)
  • TABLE 71 U.S. PATENTS BY SUBJECT AREA, JANUARY 2009 TO JANUARY 2014 (NUMBER)
  • TABLE 72 PATENT ASSIGNEES BY COUNTRY, JANUARY 2013 TO JANUARY 2014
  • TABLE 73 GLOBAL FORECAST FOR THE POC MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 74 U.S. FORECAST FOR THE POC MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 75 INTERNATIONAL FORECAST FOR THE POC MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 76 POC GLOBAL MARKET SHARE BY REGION, 2013 (%/$ MILLIONS)
  • TABLE 77 MARKET SHARE OF MAJOR POC MARKET PARTICIPANTS, 2013 (%/$ MILLIONS)
  • TABLE 78 ABAXIS' COMPANY REVENUES, 2006-2013* ($ MILLIONS)
  • TABLE 79 ABBOTT'S COMPANY REVENUES, 2006-2013 ($ MILLIONS)
  • TABLE 80 ALERE'S COMPANY REVENUES, 2006-2013 ($ MILLIONS)
  • TABLE 81 BECTON DICKINSON'S COMPANY REVENUES, 2006-2013* ($ MILLIONS)
  • TABLE 82 CHEMBIO'S COMPANY SALES, 2006-2013 ($ MILLIONS)
  • TABLE 83 CHURCH & DWIGHT'S COMPANY REVENUES, 2006-2013 ($ MILLIONS)
  • TABLE 84 DANAHER'S COMPANY REVENUES, 2006-2013 ($ MILLIONS)
  • TABLE 85 HEMOCUE ESTIMATED REVENUES, 2010-2013 ($ MILLIONS)
  • TABLE 86 JOHNSON & JOHNSON'S COMPANY REVENUES, 2006-2013 ($ MILLIONS)
  • TABLE 87 NIPRO CORP.'S COMPANY REVENUES, 2006-2013* ($ MILLIONS)
  • TABLE 88 ORASURE'S COMPANY REVENUES, 2006-2013 ($ MILLIONS)
  • TABLE 89 QUIDEL'S COMPANY REVENUES, 2006-2013 ($ MILLIONS)
  • TABLE 90 ROCHE GROUP'S REVENUES, 2006-2013 ($ MILLIONS)
  • TABLE 91 SEKISUI CHEMICAL CO.'S REVENUES, 2006-2013* ($ MILLIONS)
  • TABLE 92 SIEMENS' COMPANY REVENUES, 2006-2013* ($ MILLIONS)
  • TABLE 93 TRINITY'S COMPANY REVENUES, 2006-2013 ($ MILLIONS)

LIST OF FIGURES

  • SUMMARY FIGURE FORECAST OF THE GLOBAL POC MARKET, 2009-2018 ($ MILLIONS)
  • FIGURE 1 ESTIMATED NUMBER OF INPATIENT CARE FACILITIES AND AVAILABLE BEDS BY SELECTED COUNTRY, 2013
  • FIGURE 2 HEALTH EXPENDITURES AS PERCENTAGE OF GDP BY SELECT COUNTRY, 1980-2015 (%)
  • FIGURE 3 HEALTH EXPENDITURES AS PERCENT OF GDP BY COUNTRY: TOP 20 SPENDERS, 2011 (%)
  • FIGURE 4 HOSPITAL USAGE STATISTICS, 2003 AND 2011 (DAYS)
  • FIGURE 5 BIRTH RATES AND BIRTHS BY COUNTRY, 2013 ESTIMATES (THOUSAND/%)
  • FIGURE 6 ESTIMATED GLOBAL POPULATION BY SELECTED AGE GROUP AND SELECTED YEARS, 2000-2030 ($ MILLIONS)
  • FIGURE 7 GLOBAL POPULATION BY SELECTED COUNTRY, 2010 AND 2015 (MILLIONS)
  • FIGURE 8 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2010 (YEARS)
  • FIGURE 9 U.S. POPULATION ESTIMATES AND PROJECTIONS BY AGE GROUP, 1900 TO 2050 (THOUSANDS)
  • FIGURE 10 ESTIMATES OF EXPECTED U.S. LIFE EXPECTANCY AT BIRTH WITH PROJECTIONS BY SEX, 1990-2020 (YEARS)
  • FIGURE 11 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2013 (YEARS)
  • FIGURE 12 GLOBAL FORECAST FOR THE POC MARKET BY TEST TYPE, 2009-2018 ($ MILLIONS)
  • FIGURE 13 DISTRIBUTION OF SALES FOR THE GLOBAL POC MARKET BY TEST TYPE, 2013 (%)
  • FIGURE 14 MARKET SHARE MAJOR POC MARKET PARTICIPANTS, 2013 (%)
  • FIGURE 15 DISTRIBUTION CHANNELS: POC DIAGNOSTIC DEVICES
  • FIGURE 16 FORECAST OF THE GLOBAL POC BLOOD GAS/ELECTROLYTE TESTING MARKET, 2009-2018 ($ MILLIONS)
  • FIGURE 17 RELATIVE MARKET SHARE BLOOD GAS ANALYZER MANUFACTURERS, 2013 (%)
  • FIGURE 18 FORECAST OF THE GLOBAL POC CARDIAC MARKER TESTING MARKET, 2009-2018 ($ MILLIONS)
  • FIGURE 19 RELATIVE MARKET SHARE OF POC CARDIAC MARKER MANUFACTURERS, 2013 (%)
  • FIGURE 20 FORECAST OF THE GLOBAL CHOLESTEROL POC RAPID TEST MARKET, 2009-2018 ($ MILLIONS)
  • FIGURE 21 RELATIVE MARKET SHARE OF CHOLESTEROL POC RAPID TEST MANUFACTURERS, 2013 (%)
  • FIGURE 22 FORECAST OF THE GLOBAL DRUG AND ALCOHOL POC RAPID TEST MARKET, 2009-2018 ($ MILLIONS)
  • FIGURE 23 RELATIVE MARKET SHARE OF DRUG AND ALCOHOL POC RAPID TEST MANUFACTURERS, 2013 (%)
  • FIGURE 24 FORECAST OF THE GLOBAL POC GLUCOSE METER MARKET, 2009-2018 ($ MILLIONS)
  • FIGURE 25 RELATIVE MARKET SHARE FOR GLUCOSE METERS AND SUPPLIES MANUFACTURERS, 2013 (%)
  • FIGURE 26 FORECAST OF THE GLOBAL INFECTIOUS DISEASE POC RAPID TEST MARKET, 2009-2018 ($ MILLIONS)
  • FIGURE 27 ESTIMATED MARKET SHARE FOR THE GLOBAL POC INFECTIOUS DISEASE MARKET BY TEST TYPE, 2013 (%)
  • FIGURE 28 RELATIVE MARKET SHARE OF INFECTIOUS DISEASE POC RAPID TEST MANUFACTURERS, 2013 (%)
  • FIGURE 29 FORECAST OF THE GLOBAL INFECTIOUS DISEASE POC RAPID TEST MARKET, 2009-2018 ($ MILLIONS)
  • FIGURE 30 MARKET SHARE FOR THE GLOBAL POC PREGNANCY/FERTILITY MARKET BY TEST TYPE, 2013 (%)
  • FIGURE 31 RELATIVE MARKET SHARE OF PREGNANCY/FERTILITY POC RAPID TEST MANUFACTURERS, 2013
  • FIGURE 32 FORECAST OF THE GLOBAL HEMOGLOBIN/HEMOSTASIS POC RAPID TEST MARKET, 2009-2018 ($ MILLIONS)
  • FIGURE 33 RELATIVE MARKET SHARE OF HEMOGLOBIN/HEMOSTASIS POC RAPID TEST MANUFACTURERS, 2013 (%)
  • FIGURE 34 FORECAST OF THE GLOBAL TUMOR MARKER POC RAPID TEST MARKET, 2009-2018 ($ MILLIONS)
  • FIGURE 35 RELATIVE MARKET SHARE OF TUMOR MARKER POC RAPID TEST MANUFACTURERS, 2013 (%)
  • FIGURE 36 FORECAST OF THE GLOBAL POC URINE CHEMISTRY ANALYZER MARKET, 2009-2018 ($ MILLIONS)
  • FIGURE 37 RELATIVE MARKET SHARE OF POC URINE CHEMISTRY ANALYZER MANUFACTURERS, 2013 (%)
  • FIGURE 38 U.S. PATENTS BY POC CATEGORY, JANUARY 2009 TO JANUARY 2014 (NUMBER)
  • FIGURE 39 U.S. PATENTS BY SUBJECT AREA, JANUARY 2009 TO JANUARY 2014 (NUMBER)
  • FIGURE 40 PATENT ASSIGNEES BY COUNTRY, JANUARY 2013 TO JANUARY 2014 (NO.)
  • FIGURE 41 GLOBAL FORECAST FOR THE POC MARKET, 2009-2018 ($ MILLIONS)
  • FIGURE 42 U.S. FORECAST FOR THE POC MARKET, 2009-2018 ($ MILLIONS)
  • FIGURE 43 INTERNATIONAL FORECAST FOR THE POC MARKET, 2009-2018 ($ MILLIONS) FIGURE 44 POC GLOBAL MARKET SHARE BY REGION, 2013 (%)
  • FIGURE 45 NORTH AMERICAN POC MARKET SHARE BY COUNTRY, 2013 (%)
  • FIGURE 46 EUROPEAN POC MARKET SHARE BY COUNTRY, 2013 (%)
  • FIGURE 47 ASIAN POC MARKET SHARE BY COUNTRY, 2013 (%)
  • FIGURE 48 MARKET SHARE MAJOR POC MARKET PARTICIPANTS, 2013 (%)
  • FIGURE 49 ABAXIS' COMPANY REVENUES, 2006-2013* ($ MILLIONS)
  • FIGURE 50 ABBOTTS' COMPANY REVENUES, 2006-2013 ($ MILLIONS)
  • FIGURE 51 ALERE'S COMPANY REVENUES 2006-2013 ($ MILLIONS)
  • FIGURE 52 BECTON DICKINSON'S COMPANY REVENUES, 2006-2013* ($ MILLIONS)
  • FIGURE 53 CHEMBIO'S COMPANY SALES, 2006-2013 ($ MILLIONS)
  • FIGURE 54 CHURCH & DWIGHT'S COMPANY REVENUES, 2006-2013 ($ MILLIONS)
  • FIGURE 55 DANAHER'S COMPANY REVENUES, 2006-2013 ($ MILLIONS)
  • FIGURE 56 HEMOCUE ESTIMATED REVENUES, 2010-2013 ($ MILLIONS)
  • FIGURE 57 JOHNSON & JOHNSON'S COMPANY REVENUES, 2006-2013 ($ MILLIONS)
  • FIGURE 58 NIPRO CORP.'S COMPANY REVENUES, 2006-2013* ($ MILLIONS)
  • FIGURE 59 ORASURE'S COMPANY REVENUES, 2006-2013 ($ MILLIONS)
  • FIGURE 60 QUIDEL'S COMPANY REVENUES, 2006-2013 ($ MILLIONS)
  • FIGURE 61 ROCHE GROUP'S REVENUES, 2006-2013 ($ MILLIONS)
  • FIGURE 62 SEKISUI CHEMICAL CO.'S REVENUES, 2006-2013* ($ MILLIONS)
  • FIGURE 63 SIEMENS' COMPANY REVENUES, 2006-2013* ($ MILLIONS)
  • FIGURE 64 TRINITY'S COMPANY REVENUES, 2006-2013 ($ MILLIONS)
Back to Top